Main Uses of Desirett

Desirett is a progestogen-only pill (POP), often referred to as a "mini-pill." Its primary purpose is to provide oral contraception to prevent pregnancy. Unlike combined oral contraceptives, Desirett contains only one type of female sex hormone, a progestogen called desogestrel, and does not contain any estrogen.

Mechanism of Action

Desirett works to prevent pregnancy through two primary mechanisms:

• Inhibition of Ovulation: Most progestogen-only pills work primarily by thickening cervical mucus to prevent sperm from entering the womb, but they do not always stop the egg cell from ripening. Desirett is distinct because its dose is generally sufficient to prevent the release of an egg from the ovaries in most cases.
• Cervical Mucus Alteration: It causes a thickening of the mucus in the cervix, which creates a physical barrier that makes it difficult for sperm to reach the uterus.

Benefits and Advantages

Desirett offers specific advantages for certain populations based on its hormonal profile and efficacy:

Suitability for Estrogen Intolerance

Because Desirett does not contain estrogen, it is an option for individuals who are sensitive to estrogen or who are advised to avoid it. This includes people who experience certain side effects from combined pills or those with specific medical profiles where estrogen is not recommended.

Use During Breastfeeding

Desirett can be used by individuals who are breastfeeding. It does not appear to influence the production or the quality of breast milk, allowing for effective contraception during the postpartum period.

High Contraceptive Efficacy

Due to its ability to consistently inhibit ovulation, Desirett provides a high level of contraceptive protection when taken correctly. This makes it more effective than older generations of progestogen-only pills that relied more heavily on cervical mucus changes alone.

Who can and cannot use Desirett?

Connection to the overall eligibility profile Regulatory documents define the eligibility profile by establishing strict exclusion criteria focused on hormone-sensitive conditions, severe liver disease, and active thrombotic disorders. This official classification dictates that the drug is contraindicated for these high-risk populations. Conversely, the official labeling confirms use is permitted under the standard condition of non-pregnancy, specifically including women who are breastfeeding.

Interactions with other medicines and products

This section describes official interaction information as documented in governmental regulatory sources for Desogestrel Progestogen-Only Pills.

The drug's interaction structure is primarily defined by pharmacokinetic effects, emphasizing the critical role of the CYP3A4 enzyme system. This structure establishes mandatory timing rules and classifies contraindications based on the potential for severe interference with the hormone’s required plasma concentration or its documented effect on co-administered drugs.

Desogestrel, the active metabolite of Desirett, primarily functions by binding to and activating the progestogen receptor as an agonist. This receptor activation initiates a series of intracellular events that modulate reproductive physiology. The dominant effect involves the central inhibition of the hypothalamic-pituitary-ovarian (HPO) axis. Activation of the progestogen receptor suppresses the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This reduces the release of pituitary gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), thereby suppressing the mid-cycle LH surge. This cascade results in the inhibition of ovulation. A secondary mechanistic effect includes alterations to the cervical mucus, causing an increase in its viscosity and forming a physical barrier. Furthermore, the sustained progestogenic activity modifies the endometrial tissue, resulting in endometrial atrophy and limiting sustained proliferation.

How to Use Desirett

The 75 µg desogestrel tablet is administered via the oral route as a fixed daily dose. The regimen requires taking one film-coated tablet containing 75 µg of the active substance. The schedule is continuous: a new 28-tablet pack is commenced immediately after finishing the previous pack, ensuring there is no tablet-free interval between treatment cycles.

The frequency pattern is once daily, and the tablet must be taken at approximately the same time each day to maintain a precise 24-hour dosing interval. The instruction for initiating the regimen recommends starting intake on the first day of the menstrual cycle. The tablet is designed to be swallowed whole and can be taken independently of meals.

The use protocol contains specific constraints for maintaining regimen consistency. The administration is tied to a 12-hour window: if the dose is missed by more than 12 hours past the usual time, the missed tablet should be taken immediately, and an additional, non-hormonal barrier method is required for the subsequent seven days. Additionally, if severe vomiting or diarrhea occurs within 3 to 4 hours of taking the tablet, the event is managed according to the missed-dose protocol due to potentially incomplete absorption. This defined set of instructions dictates the standardized, long-term protocol for use.

Research Evidence / Overview of Studies for Desirett

This section provides an overview of the types of official research that have been conducted on Desirett (the desogestrel progestogen-only pill), outlining what has been studied and what remains uncertain, based on regulatory filings and scientific reviews.

Evidence for Use in Preventing Pregnancy (Contraception)

The primary research concerning Desirett was conducted through Randomized Controlled Trials (RCTs) and controlled comparative studies. These studies were set up to measure the risk of unintended pregnancy over time, often expressed as the Pearl Index (a calculation of pregnancies per 100 women over one year of use). Research explored outcomes across various populations, including women who were new to hormonal contraception and those switching from other methods.

The key findings described the measurements of the Pearl Index across the typical 9- to 13-month follow-up periods. This evidence is documented in official regulatory summaries.

Despite the documented evidence, there are aspects that remain under ongoing research. The existing major trials primarily followed women for an intermediate-term duration of around 9 to 13 treatment cycles. This means long-term outcomes tracking continuous use and compliance beyond the first year are not as extensively characterized. Additionally, research is limited in fully describing the results for specific subgroups, such as women with high Body Mass Index (BMI).

Studies on Changes to Menstrual Bleeding Patterns

Research has also explored the relationship between Desogestrel and changes in a user’s menstrual cycle. These studies included comparative trials and observational analyses that monitored women over several months. The main outcomes observed in the research involved tracking the frequency and duration of bleeding or spotting days, which were usually recorded in daily diaries. Researchers also monitored the incidence of amenorrhea (a complete absence of bleeding) over defined time intervals.

Studies report that the patterns observed were mixed and often highly variable among different subjects. Reports described that some individuals experienced amenorrhea, while others reported frequent or unscheduled spotting. Studies suggested that while the bleeding pattern tended to stabilize over the observed period, the findings describing the exact rates of amenorrhea or unscheduled bleeding varied across the available comparative studies.

Research provides limited information on the factors that contribute to the variability observed in bleeding patterns among users. Furthermore, high rates of study participant discontinuation due to these changes in bleeding pattern complicate the long-term characterization of these effects. Research provides limited direct comparative evidence against a placebo or no-treatment control for the specific purpose of examining outcomes related to pre-existing heavy menstrual bleeding.

Evidence in Special Populations: Breastfeeding Women

Specific research has examined the use of Desirett in women who are postpartum and actively breastfeeding. This evidence is often compiled from systematic reviews of existing non-randomized observational cohort studies and analyses of specific subgroups within larger trials.

Research monitored outcomes related to both the nursing mother and the infant. Reports consistently described that the data collected showed no association with key measures of infant growth during the observed follow-up periods. The research observed that the measurements of the mother's milk quantity or the duration she continued breastfeeding were not significantly changed in the study populations.

Key Studies & References

1. Progestogen-only contraception use during breastfeeding: an updated systematic review (Assessing safety during lactation and infant outcomes)
2. CPMP PUBLIC ASSESSMENT REPORT Combined oral contraceptives and venous thromboembolism (Regulatory document informing the evidence base for desogestrel use)

Common questions about Desirett (FAQ)

Q: How quickly does Desirett start to work?

A: If a user begins taking the pill on the first day of their menstrual cycle (Day 1), official guidance states that the contraceptive effect may begin immediately. If starting at any other time during the cycle, regulatory guidance advises the use of a non-hormonal barrier method, such as a condom, for the first 7 days of tablet-taking to ensure full protection.

Q: What should I do if I miss a Desirett pill?

A: The required action depends on the duration of the missed dose. If a tablet is missed by less than 12 hours from the usual time, official guidance recommends taking the missed tablet immediately, and protection remains maintained. If the dose is missed by more than 12 hours, official guidance advises that the missed tablet be taken immediately and a non-hormonal barrier method be used for the following 7 days.

Q: Can Desirett interact with common antibiotics?

A: Official regulatory documents do not list most common antibiotics as agents that reduce effectiveness. However, certain powerful enzyme-inducing medicines, such as those used for conditions like tuberculosis (e.g., Rifampicin), can accelerate the metabolism of the active hormone, thereby lowering contraceptive effectiveness.

Q: Are there any herbal supplements that interact with Desirett?

A: Yes, official product information explicitly lists the herbal product St. John’s Wort (Hypericum perforatum) as an enzyme inducer. This means it may accelerate the breakdown of the active hormone, which could reduce its concentration in the body and diminish contraceptive effectiveness.

Q: Is it normal to have spotting when starting Desirett?

A: Yes, official safety information indicates that irregular bleeding and spotting disturbances may occur more frequently when first starting treatment with Desirett. This pattern often stabilizes over the initial months of use. If bleeding is very frequent or irregular, it is important to consult a healthcare provider.

Q: Do most people get weight gain on Desirett?

A: Weight increased is listed in official documentation as a 'Common' undesirable effect. This classification means that this side effect may be reported in between 1 in 100 to less than 1 in 10 users.

Q: Is it possible for Desirett to cause acne or make it worse?

A: Acne is listed in regulatory product information as a 'Common' undesirable effect. While the pill is sometimes associated with improving acne, it is officially a reported possible side effect of the medicine.

Q: How long do side effects from Desirett usually last after starting?

A: While the exact duration varies by person and effect, regulatory safety data notes that irregular bleeding disturbances—the most common side effect—tend to occur more frequently at the beginning of treatment. This suggests that many initial side effects may subside or stabilize over the first few cycles of use.

Q: Can women over 35 safely use Desirett?

A: Unlike combined oral contraceptives (COCs) that contain estrogen, advanced age is not listed as an absolute contraindication for this progestogen-only pill. However, a person's individual risk factors, such as a history of blood clots or liver disease, are assessed before use.

Q: Is it normal to have no period at all while on Desirett?

A: The complete absence of menstruation, known as amenorrhoea, is listed in official documentation as a 'Very Common' undesirable effect, meaning it may affect 1 in 10 users or more. This is an expected outcome for some users on this type of contraceptive. If doses have been missed, consulting a healthcare provider about the need for a pregnancy test is advised.

Q: Why do some people experience breast tenderness on Desirett?

A: Breast pain or tenderness is listed as a 'Common' undesirable effect of the medication. This is related to the hormonal changes caused by the active substance, Desogestrel.

Q: Does Desirett offer protection against sexually transmitted infections (STIs)?

A: No, like all hormonal contraceptive pills, Desirett does not provide any protection against HIV infection (AIDS) or any other sexually transmitted infections (STIs). A barrier method, such as a condom, is necessary for STI protection.

Q: How long after stopping Desirett should I expect my period to return?

A: Official data suggests that the return of the normal menstrual cycle and fertility generally occurs within a short time after stopping the pill, often within the first 12 months. This is typically observed regardless of the duration or type of hormonal method used.

Q: Is Desirett considered to be a highly effective method of birth control?

A: Yes, Desirett is classified as a highly effective contraceptive method. Clinical studies measure its efficacy using the Pearl Index (the number of unintended pregnancies per 100 women-years of use), which is an important measure used to determine its efficacy when used as directed.

Q: Are there any reported long-term effects of taking Desirett?

A: The safety profile addresses potential risks associated with long-term use. These include the necessity to monitor for a potential slight increase in the risk of breast cancer diagnosis, as well as associations with hepatic tumors, which are monitored as part of the overall safety profile.

Q: Are changes in libido a reported side effect of Desirett?

A: Decreased libido is listed in official product information as a 'Common' undesirable effect. This means it may affect between 1 in 100 to less than 1 in 10 users.

Q: What is the success rate of Desirett in preventing pregnancy in real-world use?

A: The success rate is primarily determined through clinical trial data, which is expressed using the Pearl Index (the number of pregnancies per 100 women over one year of use). This metric is a key indicator used by regulators to establish the drug's effectiveness.

The storage and disposal of Desirett (desogestrel 75 microgram tablets) must strictly adhere to the conditions outlined in regulatory product information to maintain stability and prevent environmental harm.